RecruitingNot Applicable

Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia

Egypt100 participantsStarted 2025-07-01

Plain-language summary

This randomized controlled trial aims to compare the efficacy and safety of high-velocity nasal insufflation (HVNI) versus standard noninvasive ventilation (NIV) in adult patients experiencing acute exacerbations of community-acquired pneumonia (CAP) accompanied by hypoxemic respiratory failure. The primary focus is on assessing treatment failure within 48 hours, defined as the need for intubation or death. Secondary outcomes include evaluations of gas exchange parameters, patient comfort levels, duration of ICU stay, and 28-day mortality rates.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Clinical and radiographic diagnosis of CAP * Respiratory failure using partial pressure of oxygen (PaO₂) and fraction of inspired oxygen (FiO₂) is defined by a partial pressure of oxygen/fraction of inspired oxygen ratio (PaO₂/FiO₂) ≤ 300 mmHg or a respiratory rate (RR) ≥ 25/min * Informed consent obtained Exclusion Criteria: * Hemodynamic instability requiring vasopressors * Altered mental status Glasgow Coma Scale (GCS \< 13) * Contraindication to NIV or HVNI (facial trauma, recent upper airway surgery) * Do-Not-Intubate (DNI) order

What they're measuring

Treatment Failure Within 48 Hours

Timeframe: 48 hours after randomization

Trial details

NCT IDNCT06996834

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01

Contact for this trial

Ahmad M. Shaddad, MD

+0201111171930 shaddad_ahmad@yahoo.com

View on ClinicalTrials.gov More Community-acquired Pneumonia trials